SHS Gesellschaft für Beteiligungsmanagement has held the first closing of its fifth fund with capital commitments of over EUR90 million.
The Tuebingen-based medical technology investor has now reached almost two thirds of the fund’s EUR150 million target.
The fifth generation of SHS funds will focus on the life sciences and medical technology sector with investments in 12-15 companies planned.
Around half of the investors in SHS V are already invested in the company’s previous funds.
“We would like to thank the investors for their trust in us,” says Hubertus Leonhardt, SHS partner and Managing Director responsible for fundraising. “For 25 years now, we have concentrated on investments in companies in the medical technology and diagnostics sectors. We have developed extensive industry experience and trust, and also have a good sense for feasible innovations. Our portfolio companies can rely on an established network of industry experts, health insurance companies and medical opinion leaders.”
“In addition to this, we help the companies improve performance with our internationalisation know-how and expertise with regard to reimbursement and regulations as well as in the initiation of strategic partnerships.”
